A Genetic Study for Alzheimer Dementia: Case-control Study
ConditionAlzheimer Dementia (AD)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age60+
SponsorMinYoung Kim, MD, PhD
About this trial
The purpose of this study is to find out the difference in genetic test results between Alzheimer's dementia patients and healthy subjects.
The investigators want to identify genes that are importantly related to Alzheimer's dementia.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Alzheimer's dementia patient
Adult patients over 60 years old
Patients with a Alzheimer's dementia patient
Total Korean version of mini-mental state examination (K-MMSE) score less than 24
Disqualifiers
Those with severe medical conditions such as unstable conditions of the cardiovascular system, digestive system, respiratory system, endocrine system, etc., who are in poor general condition
In the case of a person with impaired consent (MMSE less than 10 points), if not accompanied by a guardian
Other cases where the researcher determines that participation in this clinical trial is not appropriate (Patients who are participating in other studies or have participated in other studies within the past 30 days can also participate in this study.)
Trial population
10 Alzheimer's dementia patients 10 healthy subjects
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
20 Participants
are grouped into 1 trial groupGroup A: Alzheimer's dementia patient and healthy subjects
Trial outcomes
Primary outcomes
1
genetic analysis
5cc blood collection for genetic testing
Time frame
BaselineSecondary outcomes
1
Measurement of Korean version of mini-mental state examination (K-MMSE)
K-MMSE is a measurement of cognitive level. Any score of 24 or more (out of 30) indicates a normal cognition. Below this, scores can indicate severe(≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment(MCI). The raw score may also need to be corrected for educational attainment and age.
Time frame
screening, Baseline2
Measurement of Clinical Dementia Rating (CDR)
CDR is a rating scale for staging patients diagnosed with dementia. The CDR evaluates cognitive, behavioral and functional aspects of Alzheimer disease and other dementias. It is calculated on the basis of testing six different cognitive and behavioral domains such as memory, orientation, judgment and problem solving, community affairs, home and hobbies performance, and personal care. The CDR is based on a scale of 0-3: no dementia (CDR = 0), questionable dementia (CDR = 0.5), MCI (CDR = 1), moderate cognitive impairment (CDR = 2) and severe cognitive impairment (CDR = 3)
Time frame
screening, Baseline3
Measurement of Geriatric Depression Scale (GDSd)
GDS is a 30-item self-report assessment used to identify depression in the elderly. One point is assigned to each answer and the cumulative score is rated on a scoring grid. The grid sets a range of 0-9 as "normal", "10-19" as "mildly depressed", and 20-30 as "severely depressed".
Time frame
BaselineLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
MinYoung Kim, MD, PhD
Lead sponsor
Bundang CHA Hospital
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: